S. 3302 · 119th Congress · Health
Mikaela Naylon Give Kids a Chance Act of 2025
- IntroducedDec 2, 2025 Done
- CommitteeReferred to Health, Education, Labor, and Pensions Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.
Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.
The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.
The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2030. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.
GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
Congressional Research Service · summary of “Introduced in Senate” version · Dec 2, 2025
Who lobbies on it
2 organizations, more than 73% of Senate bills · 4 filings · Q4 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Biotechnology Innovation Organization
2 of 4 quarters
“Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review…”
$6.5M lobbying spend in 2026 to date, all issuesQ2 2026 filing
-
Glaukos Corporation
2 of 4 quarters
“Legislation regarding FDA regulation of combination products H.R. 1261/ S. 3302 Mikaela Naylon Give Kids a Chance Act Bill”
$760K lobbying spend in 2026 to date, all issuesQ1 2026 filing
Organizations that named S. 3302 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Dec 2, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Dec 2, 2025Introduced in Senate